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Abstract: Bendamustine is an alkylating agent which also shows properties of a purine analog. 
Because of its unique mechanism of action it shows activity in relapsed indolent lymphomas 
which are resistant to alkylating agents, purine analogs, and rituximab. Bendamustine has 
a favorable toxicity proﬁ  le causing no alopecia and only a moderate hematotoxicity and 
gastrointestinal toxicity. Combinations of bendamustine with mitoxantrone and rituximab 
and with rituximab alone have been shown to be highly active in relapsed/refractory indolent 
lymphomas and mantle cell lymphomas achieving long lasting complete remissions. Because 
of only moderate toxicity these combinations can be applied safely in elderly patients who can 
be treated in an outpatient setting.
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Introduction
Indolent B-cell lymphomas are a heterogenous group of lymphoproliferative 
malignancies with a relatively good prognosis and a median survival of up to 10 years 
(Armitage et al 1993). Standard ﬁ  rst-line chemotherapy results in high response rates 
but unfortunately the disease relapses and second and further lines of chemotherapy lead 
to continously lower remission rates and shorter periods until the next anti-lymphoma 
therapy is necessary. Therefore new treatments that are highly active in the relapsed 
situation and result in long term remissions are urgently needed.
Development of bendamustine, mechanism
of action, and metabolism
Bendamustine hydrochloride was ﬁ  rst synthesized in 1963 by Ozegowski and Krebs 
in East Germany. It is a water soluble, white, microcrystalline powder with amphoteric 
properties due to a nitrogen mustard group and a butyric acid side chain. Chemically it 
is 4-{5-[bis(2-chloro-ethyl)amino]-1-methyl-2-benzimidazolyl}butyric acid (Figure 1). 
It has a nitrogen mustard moiety, a benzimidazole ring, and an alkane carboxylic acid 
side chain, which all may be responsible for its cytotoxic activity (Ozegowski and Krebs 
1963, 1971; Schnabel et al 1967). Bendamustine acts as an alkylating agent causing 
intra-strand and inter-strand cross-links between DNA bases (Hartmann et al  1972). 
Compared with other alkylating agents, bendamustine causes more cross-links and 
importantly cross-linking seems to be more durable and more difﬁ  cult to repair than those 
induced by carmustine and cyclophosphamide (Strumberg et al 1996). Treatment with 
bendamustine also leads to disruption of the matrix function of DNA in DNA synthesis 
(Hesse et al 1981). The benzimidazole ring may be responsible for the purine analog 
activity of bendamustine (Staib et al 1999), although this has not been proven deﬁ  nitely 
in vivo. It has been shown that bendamustine induces apoptosis in B-chronic lymphocytic 
leukemia cells (Schwänen et al 2002). Very recently it has been demonstrated that Therapeutics and Clinical Risk Management 2008:4(4) 728
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bendamustine has a distinct mechanism of action unrelated 
to other alkylating agents by activation of DNA damage stress 
response and apoptosis, inhibition of mitotic checkpoints, 
and induction of mitotic catastrophe (Leoni et al 2008). 
Compared with equitoxic concentrations of phosphoramide 
mustard and chlorambucil, the genes p21 (Cip1/Waf1) and 
Noxa which are responsible for apoptosis are induced much 
more strongly by bendamustine. Bendamustine also leads to a 
unique and marked phosphorylation of Ser15, which is one of 
the key events of p53-mediated apoptosis. It was shown also 
in SU-DHL-1 cells that bendamustine, but not phosphoramide 
or chlorambucil, causes an increase in the protein expression 
of Bax leading to p53 mediated apoptosis. Furthermore, 
bendamustine inhibits mitotic checkpoints and induces mitotic 
catastrophe by the inhibition of several mitosis-related genes 
like polo-like kinase 1, Aurora Kinase A, and Cyclin B1 
(Leoni et al 2008). After intravenous application bendamus-
tine undergoes an extensive ﬁ  rst-pass metabolism in the liver 
by cytochrome p450 (Preiss et al 1985). A high percentage 
of the drug (95%) is bound to protein, primarily albumin, 
but only free bendamustine is active (Haase et al 1991). 
Elimination is biphasic with a half-life of 6–10 minutes and a 
terminal half-life of approximately 30 minutes. Bendamustine 
is eliminated primarily by the renal route (Matthias et al 1995). 
Interestingly it is not necessary to reduce the bendamustine 
dose in patients with impaired renal function. Bendamustine 
doses up to 120 mg/m2 on day 1 + 2 can be given safely even 
to patients on hemodialysis (W. Pönisch, pers comm and own 
unpublished observation).
Early clinical studies 
in East Germany
Until 1990 bendamustine was available only in East Germany, 
the former German Democratic Republic. There it was used for 
the treatment of different tumors. East German investigators 
showed that it has considerable cytotoxic activity in chronic 
lymphocytic leukemia (CLL) (Anger et al 1975), Hodgkin’s 
disease (Herold et al 1992), non-Hodgkin’s lymphoma (Ruffert 
et al 1989; Brockmann 1992), multiple myeloma (Anger et al 
1967, 1969), and lung cancer (Anger et al 1975).
Bendamustine monotherapy
Apart from case reports, only a few studies have been 
published that examined the efﬁ  cacy of bendamustine as 
a monotherapy in relapsed indolent lymphomas. The ﬁ  rst 
is the study by Heider and Niederle (2001) who treated 
58 patients in the relapsed situation with bendamustine 
120 mg/m2 day 1 + 2 of a 3-week cycle. The treatment was 
repeated until complete remission (CR) or partial remis-
sion (PR) or stable disease (SD) was conﬁ  rmed on two 
consecutive cycles. Fifty-two patients were evaluable for 
response and toxicity. They reported a CR of 11% and a PR 
Figure 1 Structure of bendamustine.
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of 62%. SD was seen in 10% and progressive disease (PD) 
in 17% of the patients. The median duration of remission 
was 16 months. The main toxicities were a reversible 
grade 1–4 hematotoxicity and a grade 1 or 2 gastrointes-
tinal toxicity. The second study was reported by Bremer 
in 2002, who treated 102 relapsed patients with different 
indolent lymphomas (CLL: 15, immunocytic: 46, multiple 
myeloma: 25, others: 16). The bendamustine dose was 
60 mg/m2, days 1–5 every 4–6 weeks. A median of 4 cycles 
(1–11) were applied. The main toxicity observed was a grade 
3 or 4 hematotoxicity with anemia in 7%, thrombocytopenia 
in 12%, and leukocytopenia in 25% of the patients treated. 
Nonhematological toxicity grade 3 or 4 was seen in less than 
5% of the patients. Grade 1 or 2 nausea and vomiting was 
reported in more than 20% of the patients (Bremer 2002). 
He reported an overall response rate (ORR) of CR + PR 
of 77% with 20% stable disease and only 4% of patients 
with progressive disease. Median duration of response 
in the patients with indolent lymphoma was 39 months 
(Bremer 2002). Recently, a study examined the efﬁ  cacy of 
bendamustine in relapsed patients with rituximab-refractory 
disease and demonstrated an ORR of 84% (29% CR, 3% CR 
unconﬁ  rmed, and 53% PR) with a bendamustine dose of 
120 mg/m2 on day 1 + 2 of a 3-week cycle for 6 cycles 
(Kahl et al 2007). This study was conﬁ  rmed by another 
trial in patients with rituximab resistant disease, in which 
20% of the patients had transformed indolent lymphomas 
(Friedberg et al 2008). In this study, 76 patients were treated 
with a bendamustine dose of 120 mg/m2 on day 1 + 2 of a 
3-week cycle for 6 cycles. The authors reported an ORR of 
77% (15% CR, 19% unconﬁ  rmed CR, and 43% PR). The 
median duration of response was 6.7 months with 36% of 
the responses exceeding 1 year. In this study a grade 3 or 4 
hematologic toxcicity included neutropenia (54%), throm-
bocytopenia (25%), and anemia (12%).
Bendamustine in combination
with other cytotoxic substances
Bendamustine has been combined with different cyto-
toxic substances in the past. However, these studies are 
all small phase I/II studies with 14–82 patients each and 
no consistent response evaluation (Table 1). The combina-
tion with vincristine and prednisone was tested in 4 small 
trials with a total of 157 patients. The ORR ranged from 
66% to 90% with a CR rate of 22%–45% and a PR rate of 
41%–52% (Ruffert et al 1989; Blumenstengel et al 1998; 
Herold et al 1999; Kath et al 2000). Mitoxantrone was 
combined with bendamustine in one study showed an ORR 
of 59% (7% CR, 52% PR) (Heck et al 1998). Another 
study combined mitoxantrone/methotrexate/prednisone 
with bendamustine in 23 patients and reported an ORR 
of 48% (13% CR, 35% PR) (Kahl et al 1997). In a small 
study 14 patients were treated with a combination of 
bendamustine/idarubicine/dexamethasone with a reported 
ORR of 79% (29% CR, 50% PR) (König et al 1999). 
Bendamustine was also combined with oral etoposide 
in 38 patients with a high ORR of 97% (67% CR, 30% 
PR) (Ruffert 1999). Most extensively the combination of 
bendamustin/vincristine/prednisone has been studied by 
the OSHO group. In a phase III study the BOP regimen 
(bendamustine 60 mg/m2 days 1–5, vincristine 2 mg on day 1, 
and prednisolone 100 mg/m2 days 1–5) has been directly 
compared with the COP (cyclophosphamide, vincristine, 
and prednisone) regimen. No signiﬁ  cant differences were 
seen for ORR, remission duration, and overall survival, 
although BOP caused less toxicity. BOP caused signiﬁ  cantly less 
leukocytopenia (19% versus 34%) and alopecia (4% versus 48%) 
compared with COP (Herold et al 2006).
In vitro studies suggest that especially combinations of 
bendamustine with purine analogs could lead to a synergistic 
cytotoxicity (Chow et al 2001). So far only one phase I/II 
trial has been published by the OSHO group combining 
bendamustine with ﬂ  udarabine. They treated 29 patients with 
relapsed indolent lymphomas with different dose levels and 
Table 1 Bendamustine in combination with other cytotoxic 
substances
Author Bendamustine 
plus
N ORR (%) CR (%) PR(%)
Ruffert et al 
 (1989)
Vincistine + 
prednisone
31 90 38 52
Blumenstengel 
  et al (1998)
Vincristine + 
prednisone
22 86 45 41
Herold et al 
 (1999)
Vincristine + 
prednisone
82 66 22 44
Kath et al 
 (2000)
Vincristine + 
prednisone
22 86 45 41
Heck et al 
 (1998)
Mitoxantrone 29 59 7 52
Kahl et al 
 (1997)
Mitoxantrone + 
MTX + prednisone
23 48 13 35
König et al 
 (1999)
Dexamethasone + 
idarubicine
14 79 29 50
Ruffert (1999) Etoposide orally 38 97 67 30
Königsmann 
  et al (2004)
Fludarabine 29 77 45 32
Abbreviations: MTX, methotrexate; CR, complete remission; ORR, overal response 
rate; PR, partial remission.Therapeutics and Clinical Risk Management 2008:4(4) 730
Weide
found a maximal tolerated dose of bendamustine 30 mg/m2 
on days 1–3 and ﬂ  udarabine 30 mg/m2 on days 1–3 when 
these drugs were combined. The reported ORR rate was 
77% with 8 of 15 responders relapsing after a median time 
of 14 months. Unfortunately, a signiﬁ  cant grade 3 or 4 
hematotoxicity was observed, and 1 patient died of febrile 
neutropenia (Königsmann et al 2004).
Bendamustine in combination
with rituximab
In 1999, we treated a patient with stage IV indolent lymphoma 
resistant to alkylating agents, anthracyclines, ﬂ  udarabine, 
and rituximab with a combination of bendamustine plus 
mitoxantrone and rituximab (BMR) as ﬁ  fth-line therapy. The 
disease went into CR after the ﬁ  rst cycle and remains at CR 
until today (9+ years). This experience led to a small pilot 
study, which conﬁ  rmed the efﬁ  cacy of the BMR regimen in 
relapsed/refractory indolent lymphomas and B-cell chronic 
lymphocytic leukemia (B-CLL) (Weide et al 1999). BMR 
was applied as follows: bendamustine 90 mg/m2 day 1 + 2, 
mitoxantrone 10 mg/m2 on day 1, and rituximab 375 mg/m2 
on days 8, 15, 22, 29. BM was repeated on day 36 for 3–5 
more cycles every 28 days (1 × BMR followed by 3–5 × BM). 
The pilot phase of BMR was continued and showed a consis-
tent high anti-lymphoma activity with long lasting complete 
remissions (Weide et al 2002). An ORR of 96% with 41% CR 
and 55% PR was observed. Importantly the time to next anti-
lymphoma therapy was markedly prolonged and a signiﬁ  cant 
proportion of the study population is still in ongoing CR up 
to more than 9 years after BMR. Interestingly, 46% of the 
patients received one cycle of BMR only, which means just 
5 weeks of cytotoxic therapy, underscoring the potency of this 
chemoimmunotherapy (Weide et al 2004). The experience of 
our single center pilot study led to a multicenter phase II trial, 
which conﬁ  rmed the efﬁ  cacy of BMR in rituximab pretreated, 
relapsed, or refractory indolent lymphomas or mantle cell 
lymphomas. BMR consisted of bendamustine 90 mg/m2 on 
day 1 + 2, mitoxantrone 10 mg/m2 on day 1, and rituximab 
375 mg/m2 on day 8 every 4 weeks times 4 (4 × BMR). In this 
trial the ORR was 89% with 35% CR and 54% PR. The main 
toxicity of BMR was a reversible hematotoxicity grade 3 or  4 
(10% anemia, 78% leukocytopenia, 46% granulocytopenia, 
16% thrombocytopenia). However, hospitalizations due to 
therapy were necessary after 4% of BMR applications only 
(Weide et al 2007). Due to the observed hematotoxicity in 
pretreated patients, we have reduced the mitoxantrone dose 
in clinical practice to 6 mg/m2 which results in a signiﬁ  cant 
reduced hematotoxicity without reducing the activity of BMR 
(unpublished observation). Parallel to the development of BMR, 
Rummel et al (2002) developed the bendamustine-rituximab 
regimen (BR). In in vitro studies they could demonstrate in 
their cell line assay a synergistic cytotoxic effect when they 
applied bendamustine together with rituximab, leading to a 
markedly increased cell killing rate (Chow et al 2002; Rum-
mel et al 2002). This led to a multicenter phase II trial in 
which they could demonstrate a high anti-lymphoma activity 
of BR in indolent lymphomas and mantle cell lymphomas 
with an ORR of 90% with a CR rate of 60%. Interestingly 
they found a remarkably low hematotoxicity grade 3 or 4 
(16% leukocytopenia, 3% thrombocytopenia [Rummel et al 
2005]). BR consisted of bendamustine 90 mg/m2 days 8 + 9, 
36 + 37, 64 + 65, 92  +  93. Rituximab (375 mg/m2) was 
given on days 1, 7, 35, 63, 91, 120. These results have been 
conﬁ  rmed by other groups (Robinson et al 2005; Van der 
Jagt  et al 2006). In a subsequent randomized phase III study 
the STIL-group (Study Group Indolent Lymphoma, Germany) 
were able to demonstrate that 6 × BR (bendamustine 90 mg/m2 
on day 1 + 2, rituximab 375mg/m2 on day 1) is equally effec-
tive concerning overall response rate compared with 6 × 
R-CHOP in the ﬁ  rst-line therapy of indolent lymphomas and 
mantle cell lymphomas (Rummel et al 2007). Bendamustine 
has been combined with ﬂ  udarabine and rituximab (BFR) in 
the treatment of relapsed indolent lymphomas. In this study 
bendamustine was applied at a dose of 50 mg/m2 on days 1–3, 
ﬂ  udarabine at a dose of 25 mg/m2 days 1–3 and rituximab 
(375 mg/m2) was given on days 8, 15, 22, 29. The 
chemotherapy part (bendamustine plus ﬂ  udarabine) was 
repeated on day 57 for 4 cycles. BFR proved to be effective 
with an ORR of 76% (28% CR, 48% PR) (Kirchner et al 
2001). Unfortunately, the study could not be continued due to 
a signiﬁ  cant hematotoxicity and a high rate of serious infec-
tions (Kirchner et al pers comm). The results of the studies 
combining bendamustine with rituximab in patients with 
relapsed or refractory indolent lymphomas are summarized 
in Table 2. Future directions of bendamustine development 
could be the sequential application of a chemoimmunotherapy 
with bendamustine (BMR or BR) followed by radioimmu-
notherapy. We have treated so far 10 patients with relapsed 
or refractory indolent lymphoma and mantle cell lymphoma 
with 3 × BMR followed by 90Y-ibritumomab tiuxetan 
(ZEVALINTM) with a high response rate (6 CR, 3 PR, 1 PD) 
with durable complete remissions in 5 patients. The main 
toxicity was a reversible grade 3 or 4 hematotoxicity after 
ZEVALINTM. No blood or platelet transfusions or hospi-
tal admissions were necessary. No severe infections were 
observed (unpublished observation). Other directions could Therapeutics and Clinical Risk Management 2008:4(4) 731
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be the combination of bendamustine with bortezomib, thalido-
mide or revlimide, antiangiogenesis agents like bevacizumab, 
or new anti-B-cell-antibodies.
Conclusions
Bendamustine has enriched our armamentarium against 
relapsed indolent lymphomas remarkably due to its unique 
mechanism of action. Especially because of its activity in 
lymphomas resistant to alkylating agents, purine analogs, 
and rituximab, it opens up an opportunity for patients 
who are normally very difﬁ  cult to treat. Of utmost importance 
are combinations of bendamustine with rituximab, which have 
shown to be highly active in achieving long lasting remissions. 
Due to a positive toxicity proﬁ  le these combinations are espe-
cially suitable for the treatment of elderly patients.
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